Literature DB >> 10200022

Anaphylaxis from yellow fever vaccine.

J M Kelso1, G T Mootrey, T F Tsai.   

Abstract

BACKGROUND: There are very few reports of anaphylactic reactions to yellow fever (YF) vaccine in the literature, and these date from the 1940s.
OBJECTIVE: We sought to estimate the rate of YF vaccine-related anaphylaxis.
METHODS: All reports of adverse reactions to YF vaccine submitted to the Vaccine Adverse Event Reporting System between 1990 and 1997 were reviewed for those meeting criteria for probable or possible anaphylactic reactions.
RESULTS: Of 243 reports submitted, 40 describe probable or possible anaphylactic reactions. In 22 of these 40, YF vaccine was the only vaccine administered. There were 5,236,820 doses of YF vaccine distributed in the United States during this period. By using all 40 cases, the rate of YF vaccine-related anaphylaxis would be 40 in 5, 236,820 or about 1 in 131,000. In 35 of the reports, information was provided on whether previous doses of YF vaccine had been given. In 34 of these 35, the reaction occurred after the first dose of YF vaccine, suggesting that vaccine constituents other than the viral proteins may have been the allergens. The vaccine is grown in chicken embryos and contains gelatin as a stabilizer.
CONCLUSION: YF vaccine can cause anaphylactic reactions. Persons presenting for YF vaccine should be asked if they have had adverse reactions to previous doses of this or other vaccines and if they are allergic to eggs, chicken, or gelatin. Health care workers administering YF vaccine should be prepared to recognize and treat anaphylactic reactions should they occur.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200022     DOI: 10.1016/s0091-6749(99)70245-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  18 in total

1.  Vaccination in Travelers.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.725

2.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 3.  The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins; Dave Jackson; Tyler Williamson
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

4.  STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  This Statement Was Prepared By P Charlebois
Journal:  Can Commun Dis Rep       Date:  2013-03-05

5.  Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.

Authors:  P Charlebois
Journal:  Can Commun Dis Rep       Date:  2010-10-02

Review 6.  Current understanding of egg allergy.

Authors:  Jean-Christoph Caubet; Julie Wang
Journal:  Pediatr Clin North Am       Date:  2011-04       Impact factor: 3.278

7.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

8.  Anaphylaxis following quadrivalent human papillomavirus vaccination.

Authors:  Julia M L Brotherton; Mike S Gold; Andrew S Kemp; Peter B McIntyre; Margaret A Burgess; Sue Campbell-Lloyd
Journal:  CMAJ       Date:  2008-09-01       Impact factor: 8.262

9.  President's address: travel medicine and principles of safe travel.

Authors:  Herbert L DuPont
Journal:  Trans Am Clin Climatol Assoc       Date:  2008

Review 10.  Vaccine-associated hypersensitivity.

Authors:  Michael M McNeil; Frank DeStefano
Journal:  J Allergy Clin Immunol       Date:  2018-02       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.